De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Adaptimmune Therapeutics Beheer
Beheer criteriumcontroles 3/4
De CEO Adaptimmune Therapeutics' is Ad Rawcliffe, benoemd in Sep2019, heeft een ambtstermijn van 5.08 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.77M, bestaande uit 23.4% salaris en 76.6% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.1% van de aandelen van het bedrijf, ter waarde $ 252.61K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.8 jaar en 9.6 jaar.
Belangrijke informatie
Ad Rawcliffe
Algemeen directeur
US$2.8m
Totale compensatie
| Percentage CEO-salaris | 23.4% |
| Dienstverband CEO | 5.1yrs |
| Eigendom CEO | 0.1% |
| Management gemiddelde ambtstermijn | 4.8yrs |
| Gemiddelde ambtstermijn bestuur | 9.6yrs |
Recente managementupdates
Recent updates
The Market Doesn't Like What It Sees From Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Revenues Yet As Shares Tumble 31%
Sep 26
Adaptimmune's T-Cell Therapy Journey: A Small Market, Big Ambitions
Sep 12Adaptimmune: How The Story Is Shaping Up For The Latter Half Of 2024
Jul 03Adaptimmune: Huge Opportunity Amid Their Setback With Genentech
Apr 26Benign Growth For Adaptimmune Therapeutics plc (NASDAQ:ADAP) Underpins Stock's 29% Plummet
Apr 16Adaptimmune Therapeutics plc (NASDAQ:ADAP) Stock Catapults 107% Though Its Price And Business Still Lag The Industry
Feb 22Adaptimmune: Drug Approval Now Imminent?
Feb 02Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Dec 27News Flash: Analysts Just Made A Notable Upgrade To Their Adaptimmune Therapeutics plc (NASDAQ:ADAP) Forecasts
Nov 09New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)
Mar 08Adaptimmune Therapeutics (NASDAQ:ADAP) Is In A Good Position To Deliver On Growth Plans
Feb 20New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)
Nov 09Adaptimmune Therapeutics: Depressed Despite Upcoming BLA
Sep 20We're Interested To See How Adaptimmune Therapeutics (NASDAQ:ADAP) Uses Its Cash Hoard To Grow
Sep 15Need To Know: The Consensus Just Cut Its Adaptimmune Therapeutics plc (NASDAQ:ADAP) Estimates For 2022
Aug 10Gene editing companies benefitting from Roche deal with CAR-T player Poseida Therapeutics
Aug 03Adaptimmune: Underappreciated Biotech With BLA Filing Q4 Of 2022
Jun 29Finally Returning To Adaptimmune Therapeutics Ahead Of Anticipated BLA
Jun 19Adaptimmune Therapeutics: A Little More Patience May Be Profitable
Mar 06Circling Back On Adaptimmune Therapeutics
Dec 15We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate
Dec 02Adaptimmune Therapeutics: Diverse Pipeline With Approval Looming
Sep 29We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate
Aug 14Adaptimmune Therapeutics: T-Cell Therapy Pioneer Boasts A Deep Pipeline, ESMO Approaches
Jul 29Adaptimmune Therapeutics: Still The TCR Leader, And With Major Upcoming Catalysts
Jun 16Adaptimmune Therapeutics (ADAP) Investor Presentation - Slideshow
Jun 05Adaptimmune slips as Barclays initiates with an underweight rating
May 28Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$72m |
| Mar 31 2024 | n/a | n/a | -US$163m |
| Dec 31 2023 | US$3m | US$650k | -US$114m |
| Sep 30 2023 | n/a | n/a | -US$95m |
| Jun 30 2023 | n/a | n/a | -US$91m |
| Mar 31 2023 | n/a | n/a | -US$114m |
| Dec 31 2022 | US$3m | US$650k | -US$165m |
| Sep 30 2022 | n/a | n/a | -US$175m |
| Jun 30 2022 | n/a | n/a | -US$176m |
| Mar 31 2022 | n/a | n/a | -US$171m |
| Dec 31 2021 | US$4m | US$617k | -US$158m |
| Sep 30 2021 | n/a | n/a | -US$156m |
| Jun 30 2021 | n/a | n/a | -US$149m |
| Mar 31 2021 | n/a | n/a | -US$140m |
| Dec 31 2020 | US$3m | US$574k | -US$130m |
| Sep 30 2020 | n/a | n/a | -US$123m |
| Jun 30 2020 | n/a | n/a | -US$127m |
| Mar 31 2020 | n/a | n/a | -US$138m |
| Dec 31 2019 | US$2m | US$500k | -US$137m |
| Sep 30 2019 | n/a | n/a | -US$144m |
| Jun 30 2019 | n/a | n/a | -US$99m |
| Mar 31 2019 | n/a | n/a | -US$102m |
| Dec 31 2018 | US$1m | US$457k | -US$96m |
| Sep 30 2018 | n/a | n/a | -US$87m |
| Jun 30 2018 | n/a | n/a | -US$93m |
| Mar 31 2018 | n/a | n/a | -US$69m |
| Dec 31 2017 | US$2m | US$444k | -US$70m |
Compensatie versus markt: De totale vergoeding ($USD 2.77M ) Ad } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 1.49M ).
Compensatie versus inkomsten: De vergoeding van Ad is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Ad Rawcliffe (52 yo)
5.1yrs
Tenure
US$2,774,041
Compensatie
Mr. Adrian G. Rawcliffe, also known as Ad, has been the Chief Executive Officer and Director of Adaptimmune Therapeutics plc since September 1, 2019. He had been the Chief Financial Officer of Adaptimmune...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO, Principal Accounting Officer & Director | 5.1yrs | US$2.77m | 0.10% $ 244.9k | |
| Co-Founder & Chief Business & Strategy Officer | no data | US$1.18m | 0.12% $ 276.5k | |
| Chief Financial Officer | 4.5yrs | US$1.17m | 0.0063% $ 14.8k | |
| Chief Operating Officer | 7.6yrs | US$1.22m | 0.064% $ 151.3k | |
| Chief Medical Officer | 4.8yrs | US$1.18m | 0.037% $ 87.2k | |
| Chief Scientific Officer | 2.4yrs | geen gegevens | 0.0049% $ 11.5k | |
| VP of Corporate Affairs & Investor Relations | no data | geen gegevens | geen gegevens | |
| Senior VP & General Council | 9yrs | geen gegevens | geen gegevens | |
| Senior Director of Corporate Communications | no data | geen gegevens | geen gegevens | |
| Chief Patient Supply Officer | 5.2yrs | US$1.72m | 0.053% $ 125.5k | |
| Senior Vice President of Late Stage Development | 4.8yrs | geen gegevens | geen gegevens | |
| Chief Commercial Officer | less than a year | US$2.19m | 0.015% $ 35.3k |
4.8yrs
Gemiddelde duur
54yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van ADAP wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.8 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO, Principal Accounting Officer & Director | 5.1yrs | US$2.77m | 0.10% $ 244.9k | |
| Independent Chairman of the Board of Directors | 9.7yrs | US$174.83k | 0% $ 0 | |
| Independent Non-Executive Director | 9.7yrs | US$111.54k | 0% $ 0 | |
| Independent Non-Executive Director | 9.6yrs | US$128.80k | 0.0093% $ 22.0k | |
| Member of the Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of the Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Independent Non-Executive Director | 6.3yrs | US$117.25k | 0% $ 0 | |
| Member of the Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of the Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of the Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of the Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of the Scientific Advisory Board | no data | geen gegevens | geen gegevens |
9.6yrs
Gemiddelde duur
59.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van ADAP wordt beschouwd als ervaren (gemiddelde ambtstermijn 9.6 jaar).